Cargando…
Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer
Primary liver cancer (PLC) is one of the most common malignant tumors, which clinically characterized by occult onset, rapid development, easy recurrence and poor prognosis. With the rapid development of tumor immunotherapy research, tumor immunotherapy has also achieved remarkable clinical efficacy...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561712/ https://www.ncbi.nlm.nih.gov/pubmed/36246617 http://dx.doi.org/10.3389/fgene.2022.1005658 |